Sökning: onr:"swepub:oai:DiVA.org:uu-357268" >
Efficient clearence...
Efficient clearence of A beta protofibrils in A beta PP-transgenic mice treated with a brain-penetrating bifunctional antibody
-
- Syvänen, Stina (författare)
- Uppsala universitet,Geriatrik
-
- Hultqvist, Greta, 1980- (författare)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap
-
- Gustavsson, Tobias (författare)
- Uppsala universitet,Geriatrik
-
visa fler...
-
- Gumucio, Astrid (författare)
- Uppsala universitet,Geriatrik
-
- Laudon, Hanna (författare)
- BioArctic AB, Stockholm, Sweden
-
- Söderberg, Linda (författare)
- BioArctic AB, Stockholm, Sweden
-
- Ingelsson, Martin (författare)
- Uppsala universitet,Geriatrik
-
- Lannfelt, Lars (författare)
- Uppsala universitet,Geriatrik,BioArctic AB, Stockholm, Sweden
-
- Sehlin, Dag, 1976- (författare)
- Uppsala universitet,Geriatrik
-
visa färre...
-
(creator_code:org_t)
- BIOMED CENTRAL LTD, 2018
- 2018
- Engelska.
-
Ingår i: Alzheimer's Research & Therapy. - : BIOMED CENTRAL LTD. - 1758-9193. ; 10
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Amyloid-beta (A beta) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD) Despite recent progress targeting aggregated forms of A beta, low antibody brain penetrance remains a challenge In the piesent study, we used transferrin receptor (TfR)-mediated transcytosis to facilitate brain uptake of our previously developed A beta protofibril-selective mAb158, with the aim of increasing the efficacy of immunotherapy directed toward soluble A beta protofibills. Methods: A beta protein precursor (A beta PP)-transgenic mice (tg-ArcSwe) were given a single dose of mAb158, modified for TfR-mediated transcytosis (RmAb158-scFvSDB), in companson with an equimolar dose or a tenfold higher dose of unmodified recombinant mAb158 (RmAb158) Soluble A beta protofibrills and total A beta in the brain were measured by enzyme-linked immunosorbent assay (ELISA) Brain distribution of radiolabeled antibodies was visualized by positron emission tomography (PET) and ex vivo autoiadiography. Results: ELISA analysis of Tris-buffered saline brain extracts demonstrated a 40% reduction of soluble A beta protofibrils in both RmAb158-scFv8D3- and high-dose RmAb158-treated mice, whereas there was no A beta protofibril reduction in mice treated with a low dose of RmAb158. Further, ex vivo autoradiography and PET imaging revealed diffeient brain distribution patterns of RmAb158-scFv8D3 and RmAb158, suggesting that these antibodies may affect A beta levels by different mechanisms. Conclusions: With a combination of biochemical and imaging analyses, this study demonstrates that antibodies engineered to be transported across the blood brain barrier can be used to increase the efficacy of A beta immunotherapy. This strategy may allow for decreased antibody doses and thereby reduced side effects and treatment costs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Geriatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Geriatrics (hsv//eng)
Nyckelord
- Alzheimer's disease (AD)
- Immunotherapy
- Amyloid-beta (A beta)
- Oligomers
- Protofibrils
- Monoclonal antibody
- Blood-brain barrier (BBB)
- Transferrin receptor (TfR)-mediated transcytosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Syvänen, Stina
-
Hultqvist, Greta ...
-
Gustavsson, Tobi ...
-
Gumucio, Astrid
-
Laudon, Hanna
-
Söderberg, Linda
-
visa fler...
-
Ingelsson, Marti ...
-
Lannfelt, Lars
-
Sehlin, Dag, 197 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Geriatrik
- Artiklar i publikationen
-
Alzheimer's Rese ...
- Av lärosätet
-
Uppsala universitet